key: cord-0860675-mx9otbmt
authors: Farrukh, Larabe; Mumtaz, Aqsa; Sana, Muhammad K.
title: How strong is the evidence that it is possible to get SARS‐CoV‐2 twice? A systematic review
date: 2021-01-02
journal: Rev Med Virol
DOI: 10.1002/rmv.2203
sha: aeaf9f17d0c2fd5a781542a2fdc20943b853948c
doc_id: 860675
cord_uid: mx9otbmt

With a large number of coronavirus disease 2019 (Covid‐19) patients being discharged from hospital with negative test results for SARS‐CoV‐2, it has been reported that several recovered cases tested positive after discharge (re‐positive, RP). This finding has raised several important questions for this novel coronavirus and Covid‐19 disease. In this review, we have discussed several important questions, including: (1) Can the virus re‐infect recovered individuals? (2) What are the possible causes of the re‐positive reverse transcriptase‐polymerase chain reaction (RT‐PCR) test in recovered patients? (3) What are the implications of these re‐positive cases concerning the spread of the virus? Understanding how recovery from Covid‐19 confers immunity to decrease the risk of re‐infection is needed to inform current efforts to safely scale back population‐based interventions, such as physical distancing. We have also described what is currently known about the immune response to Covid‐19, highlighted key gaps in knowledge, and identified opportunities for future research. Overall, the quality of the evidence is poor and we describe the features that should be described for future cases.

outbreak to be a pandemic. Extreme control measures were taken, resulting in grave consequences both in terms of health outcomes and financial losses. The SARS-CoV-2, in general, is a mild infection, however, some patients, especially those in the elderly group (>60 years old) with co-morbidities, are prone to develop more severe symptoms of the disease. 2, 3 Although the global daily case fatality rate (CFR) of the ongoing Covid-19 pandemic is declining, there are many countries where CFR is still increasing, and the rate of new infections is significantly high. 4 Recently, a large number of recovered patients with have been discharged from the hospital, with regular follow-up and observation. 2 Surprisingly, a re-positive (RP) result of the SARS-CoV-2 RNA test has been reported in some of these patients, most of whom had complete clinical remission and two consecutive negative nasopharyngeal swabs on discharge. 2 Although the number of these RP patients is small, their potential impact and significance are high.

These RP patients generally belong to a younger age group and present initially with mild or moderate symptoms. 1 No patients who experienced severe symptoms of the disease initially have so far become RP. Retrospectively, it was documented that the RP patients displayed milder symptoms and earlier RNA negative-conversion as compared to NRP patients. When re-admitted to the hospital, these RP patients did not display any significant clinical symptoms, but showed normal or improving CT imaging and decreasing inflammatory cytokines. 2 Although PCR-based methods cannot distinguish between the infectious form of the virus and the non-infectious nucleic acid, the positive RT-PCR of these recovered patients represents an important finding that should be studied in detail. Few studies so far have investigated the contagiousness of these RP patients but, if they carry live viruses, they might be a potential source of infection to the general population. In this article, we review potential reasons why the results of the SARS-CoV-2 RT-PCR tests were positive again in recovered patients.

The review was done to study the possibility of re-infection in patients diagnosed with Covid-19, after being discharged from the hospital. In this article, we discuss in detail all the possible causes that could result in a re-positive RT-PCR in these convalescent patients after meeting the recent discharge criteria. 

A total of 206 studies was imported into Endnote from the two databases. Inclusion and exclusion criteria were applied and a total of 42 articles was selected after going through titles and abstracts. These 42 full articles were extracted and independently passed through the quality assessment questionnaire to finally select a total of 27 articles included in the final review. Figure 1 shows the PRISMA flow chart of study selection.

Data extraction was done from selected studies in tabulated form.

Extraction of data was performed by the same review authors who conducted the study selection independently, using a structured form that contained study characteristics, including the age of the patients, presence of fever, presenting symptoms, vitals, CT scan findings, and management. Any disagreement was discussed after completion of the data collection process and reviewers were consulted for each topic.

A total of 27 studies was included in our review, reporting a total of 253 cases who tested positive the second time after an average period of 11.5 days from the last negative RT-PCR test. The mean age of the RP positive cases was 47.85 years ( Table 2 ). The sample most commonly collected was oropharyngeal swab (n = 25/253) followed by nasopharyngeal (n = 21/253) and in a few cases, saliva (n = 1), sputum (n = 2), or feces (n = 4); Table 3 ). In a few cases, samples from different sites were collected to reconfirm the initial positive results while in others the samples collected from secondary sites were positive suggesting viral shedding.

Data of initial presentation was available for 29, of whom 28 cases were symptomatic. Twenty-eight were febrile on the first presentation, six were afebrile while no data were available for the rest. There were significant findings on chest computed tomography (CT) scan in 18 patients with varying degrees of focal unilateral involvement, focal bilateral involvement, and diffuse bilateral lung involvement. They were initially managed with oxygen (n = 7), antibiotics (n = 6), antivirals (n = 11), steroids (n = 10), traditional 

Covid-19 has affected more than 55 million people worldwide with deaths exceeding one million. 5 The chance of getting re-infected with the same virus poses a threat of another wave of the pandemic and has been a source of concern. In our study, we assessed whether reinfection is possible and other immunological, virological, and sampling errors which might have led to RP result.

There is a possibility of RT-PCR rendering false-negative results, due to improper sampling procedures, sources of samples, or poor sensitivity/specificity of the nucleic acid test kit.

The low sensitivity of commercial RNA detection kits has been speculated to be one of the major causes of RP. 6 of RT-PCR results for SARS-CoV-2 detection has been recorded. 8 Therefore, future studies should improve both the sensitivity and specificity of the detection kit. 

The PCR test relies on the amplification of nucleic acid in the sample, 

Viral load is a strong indicator of the severity of infection. 17 Normally, PCR testing amplifies the genetic material from the collected specimen in cycles; the fewer the cycles required to detect it, the greater will be the initial viral load. 18 

One potential reason for RP is intermittent viral shedding. The GI system is one of the main potential shedding sites due to the presence of ACE-2 receptors. 19 Xing et al. 20 

A mutation that can affect the biological conformation of the virus leading to altered infectivity and immunogenicity is called a strain, otherwise, it is called a variant. A total of 106 variants and 68 strains has been identified so far with most having little to no impact on the virulence of the virus. 27 As the cases of Covid-19 are now rising exponentially, recurrences due to different strains have also been reported. 27 In August, a 33-year-old man was diagnosed again with Covid-19

in Hong Kong after 142 days since the initial infection. 28 After an initially mild symptomatic episode in March 2020, he recovered and the serological testing did not reveal any detectable antibodies. In

August 2020, he was tested positive on entry screening at the airport, after his return trip to Europe. The genomic testing revealed mutated viral particles making this the first confirmed case of reinfection due to a different strain. In comparison, there were four amino acid residues that differed in the spike protein between the first and second infection, including L18F, A222V, D614G, and Q780E. The A222V and D614G mutations affecting the spike protein of the virus were said to be significant in evading the immune response and causing reinfection. While there is no significant data on A222V mutation apart from the fact that A222V mutation occurs in one of the viral spike proteins that T-cells target, the D614G mutation has been studied widely. 29 The original stain of the virus from Wuhan had the D614 variant. The D614G mutation changed the amino acid at position 614 from D (aspartic acid) to G (glycine)

giving birth to a new G614 strain. The mutation initially occurred in Europe and gradually noticed to be on the rise in North America, Oceania, and then Asia. 30 Currently, 70% of the general population has this mutation. The G614 mutation has been infamous for its increased infectivity, viral load, and rapid spread among the general population while further studies are been conducted to observe the difference in virulence. 31 After the aforementioned case, reports of recurrent cases with a different strain emerged from Belgium, Nevada, Ecuador, and India. 32 

Antibodies against other coronaviruses can wane over time (range:

12-52 weeks from the onset of symptoms). 37 the protective effect of prior vaccines, particularly BCG vaccine on the immune system. BCG increases the immune response to pathogens other than TB and conferring nonspecific protection against a wide range of infections by activating the innate immune system. It also helps the innate immune system to develop a 'memory' against other microorganisms, a phenomenon known as trained innate immunity. 40 41 This hypothesis requires multiple scientific trials for confirmation. Furthermore, in lieu of the multiple mutated strains, highly sensitive antibody testing methods should be devised to detect antibodies against a range of epitopes found on multiple viral proteins. This will not only help us in studying protective immune response but also help in the development of suitable vaccines and the protection they confer. We can then assess the longevity of protective antibodies produced after vaccination.

While the initial cases of re-positives can be due to sampling errors, 

Clinical characteristics of the recovered COVID-19 patients with re-detectable positive RNA test

A bibliometric analysis of Covid-19 research activity: a call for increased output

Recurrence of positive SARS-CoV-2 RNA in COVID-19: a case report

On the potential role of exosomes in the COVID-19 reinfection/reactivation opportunity

Coronavirus Update (live): 58,949,581 cases and 1,393,073 deaths from COVID-19 virus pandemic

New IgM seroconversion and positive RT-PCR test after exposure to the virus in recovered COVID-19 patient

Efficacy of Serology Testing in Predicting Reinfection in Patients With SARS-CoV-2. Disaster Medicine and Public Health Preparedness

Recurrence of positive SARS-CoV-2 in patients recovered from COVID-19

Interim guidelines for collecting, handling, and testing clinical specimens for COVID-19

Re-evaluation of retested nucleic acidpositive cases in recovered COVID-19 patients: report from a designated transfer hospital in Chongqing

Assay Techniques and Test Development for COVID-19 Diagnosis

Re-positive coronavirus disease 2019 PCR test: could it be a reinfection? New Microbes and New Infections

A review of viral shedding in resolved and convalescent COVID-19 patients

Time kinetics of viral clearance and resolution of symptoms in novel coronavirus infection

Virological assessment of hospitalized patients with COVID-2019

European Centre for Disease Prevention and Control. Reinfection with SARS-CoV: Considerations for public health response. ECDC

Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury

Your coronavirus test is positive. Maybe it shouldn't be. The New York Times

The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes

Prolonged presence of SARS-CoV-2 in feces of pediatric patients during the convalescent phase

Viral load of SARS-CoV-2 in clinical samples

Persistent viral shedding of SARS-CoV-2 in faeces -a rapid review

Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes

Serial CT features in discharged COVID-19 patients with positive RT-PCR re-test

Case Report: Viral Shedding for 60 Days in a Woman with COVID-19

Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19)

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing

Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors

Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus

MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets

Genomic evidence for reinfection with SARS-CoV-2: a case study. The Lancet Infectious Diseases

Asymptomatic Reinfection in 2 Healthcare Workers From India With Genetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2. Clinical Infectious Diseases

COVID-19 re-infection by a phylogenetically distinct SARS-CoV-2 variant. First Confirmed Event in South America

Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain

A Case of Early Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases

The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection

Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease

Humoral Immune Response to SARS-CoV-2 in Iceland

Trained innate immunity, epigenetics, and Covid-19

Coinfection of tuberculosis pneumonia and COVID-19 in a patient vaccinated with Bacille Calmette-Guérin (BCG): case report

Re-infection by COVID-19: a real threat for the future management of pandemia? Infect Dis (Lond)

A case presentation for positive SARS-CoV-2 RNA recurrence in a patient with a history of type 2 diabetes that had recovered from severe COVID-19

Recurrence or Relapse of COVID -19 in Older Patients: A Description of Three Cases

Positive SARS-CoV-2 RNA recurs repeatedly in a case recovered from COVID-19: dynamic results from 108 days of follow-up

Recurrence of COVID-19 after recovery: a case report from Italy

A novel coronavirus from patients with pneumonia in China

Recurrent presence of SARS-CoV-2 RNA in a 33-year-old man

Recurrent pneumonia in a patient with new coronavirus infection after discharge from hospital for insufficient antibody production: a case report

Seven discharged patients turning positive again for SARS-CoV-2 on quantitative RT-PCR

A case of a readmitted patient who recovered from COVID-19 in Chengdu

Positive SARS-Cov-2 test in a woman with COVID-19 at 22 days after hospital discharge: A case report

The clinical features and outcomes of discharged coronavirus disease 2019 patients: a prospective cohort study

Positive RT-PCR test results in patients recovered from COVID-19

Chest CT and clinical follow-up of discharged patients with COVID-19 in Wenzhou City

Recurrent positive SARS-CoV-2: immune certificate may not be valid

The issue of recurrently positive patients who recovered from COVID-19 according to the current discharge criteria: investigation of patients from multiple medical institutions in Wuhan

A case series of recurrent viral RNA positivity in recovered COVID-19 Chinese patients

Clinical Characteristics and Imaging Findings of 35 Patients Recovered from COVID-19 with Recurrent Positive RT-PCR Test Results

Recurrence of positive SARS-CoV-2 viral RNA in recovered COVID-19 patients during medical isolation observation

Clinical characteristics on 25 discharged patients with COVID-19 virus returning

Positive result of Sars-Cov-2 in faeces and sputum from discharged patient with COVID-19 in Yiwu

Re-evaluation of retested nucleic acidpositive cases in recovered COVID-19 patients: Report from a designated transfer hospital in Chongqing

False negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: Rather than recurrence

How to cite this article: Farrukh L, Mumtaz A, Sana MK. How strong is the evidence that it is possible to get SARS-CoV-2 twice? A systematic review

The authors thank our colleagues from King Edward Medical University who provided insight and expertise that greatly assisted the research. The authors thank Professor Paul Griffiths for his assistance with the comments that greatly improved the manuscript.They would also like to show our gratitude to our team for sharing their pearls of wisdom with us during the course of this research, and also thank our reviewers for their invaluable insights.

This manuscript has not been previously published and has not been 

L.F. and A.M. contributed equally in designing the study, database screening, data extraction, and writing manuscript. M.K.S. critically reviewed the paper for the final submission.

https://orcid.org/0000-0001-7044-8482Muhammad K. Sana https://orcid.org/0000-0003-1952-8203